CLEARBRIDGE HEALTH LIMITED
(Company Registration No. 201001436C)

ANNOUNCEMENT PURSUANT TO RULE 706A OF THE LISTING MANUAL

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), the board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**") wishes to announce the following sale of shares in a subsidiary during the half year ended 30 June 2020:

DISPOSAL OF SUBSIDIARY

On 27 March 2020, the Company announced that its wholly-owned subsidiary, SAM Laboratory Pte. Ltd. ("**SAM**"), had entered into a conditional sale and purchase agreement with Biolidics Limited (the "**Purchaser**") for the acquisition by the Purchaser of the entire issued and paid-up ordinary shares (the "**Sale Shares**") in the capital of Biomedics Laboratory Pte. Ltd. ("**Biomedics**") held by SAM (the "**Disposal**"). The Disposal was completed on 26 May 2020. The details of the Disposal are set out below:

Consideration	The aggregate consideration for the Sale Shares is S$3,500,000 (the "**Consideration**"). Where the Deferred Consideration (as defined below) is paid after 12 months from the date of completion of the Disposal (the "**Completion Date**"), the Consideration shall be S$3,700,000. The Consideration shall be satisfied in full by way of bank transfer of immediately available funds to an account designated by SAM as follows: (a) S$100,000 shall be payable upon completion ("**Initial Payment**"); and (b) the remaining amounts being the Consideration less the Initial Payment (the "**Deferred Consideration**") shall be payable no later than 24 months from the Completion Date. For the avoidance of doubt, the Purchaser has the option to satisfy the Deferred Consideration at any time after completion by providing not less than 10 days of written notice to SAM of such payment. The Consideration was based on arm's length negotiations and arrived at on a willing seller willing buyer basis, after taking into consideration, amongst others, the net assets value of Biomedics, the initial acquisition cost of Biomedics' current business (the "**Initial Acquisition**"), the expanded range of services, customer base and revenue growth of the clinical laboratory business since the Initial Acquisition, and the market value of the Sale Shares based on a valuation report issued by an independent valuer appointed by the Purchaser.
Net assets value	Based on the management accounts as at 31 December 2019, the net tangible assets and net asset value of Biomedics were S$400,001 and S$2,415,000 respectively.

Please refer to the Company's announcement dated 27 March 2020 in relation to the Disposal for further details.

BY ORDER OF THE BOARD

Yee Pinh Jeremy
Chief Executive Officer and Executive Director

14 August 2020

---

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the SGX-ST Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*